Gedeon Richter Vietnam Company LTD

Headquartered in Hungary, Gedeon Richter Plc. is an innovation-driven specialty pharmaceutical company.

Richter in Vietnam has 3 key values: Reliability, Responsibility and Innovation.

Reliability: from 1955, the drugs of Gedeon Richter Plc have been available in Vietnam with uninterrupted supply. Since 1995 Gedeon Richter Plc. has been represented in Vietnam directly with 2 Representative Offices in Ho Chi Minh and Hanoi City. As a milestone, in 2021-2022, Richter established new foreign invested enterprise and importing warehouse in Vietnam.

Responsibility: We do our best to serve Vietnamese healthcare. Richter is committed to providing affordable, high-quality medicines. Besides we provide donations and support in continuous education, expand medical knowledge of healthcare professional and patients.

Innovation: Richter is continuously bringing innovative drugs to Vietnam in the field of Women’s Healthcare, Central Nervous System and Cardiology. Our 3 key areas in Vietnam include therapies for women’s health, for the health of brain and nervous function and drugs for healthy hearts. Our newest original medicine in Vietnam is an antipsychotic developed by Richter. This unique drug is wider and wider used all around the world especially in USA and now available for Vietnamese patients as well.

The activities of the Hungarian-directed multinational company are vertically integrated and involve pharmaceutical manufacturing, research and development, sales and marketing. Richter’s goal is to help the public fight off illnesses with innovative products and, by doing so, help improve the quality of human life.

The company has network covering 5 continents with direct presence in more than 50 countries. Gedeon Richter has 8 manufacturing and R&D sites.

The company manufactures about 200 pharmaceutical products in more than 400 formulations. The products of the company are available in more than 100 countries around the World. Richter’s consolidated sales were approximately EUR 1.8 billion in 2021.

The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system and cardiovascular areas.

As a regional leader in R&D, Richter’ original research activity focuses on central nervous system disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.

For more information:  https://www.gedeonrichter.com/en